Timing note: AbbVie is scheduled to report today, Friday, July 31, 2026, before the market opens—not tomorrow. The earnings call is scheduled for 8:00 a.m. Central Time. (investors.abbvie.com)
AbbVie enters Q2 with excellent operating momentum but a higher bar than it faced earlier this year. The central question is no longer whether the company can replace Humira: Skyrizi and Rinvoq are clearly doing that. Instead, investors need to determine whether their growth can continue exceeding an increasingly demanding outlook while neuroscience broadens AbbVie’s growth base.
A satisfactory report probably requires more than an EPS beat. The bullish outcome would combine:
| Metric | Q2 expectation/reference point | Year-over-year implication |
|---|---|---|
| Revenue | Approximately $16.7B–$16.8B | About 8% growth |
| Adjusted EPS, including known Q2 IPR&D | $3.57–$3.61 company guidance; published consensus around $3.61 | About 21% growth at midpoint |
| Adjusted EPS before the new Q2 IPR&D charge | $3.74–$3.78 | About 27% growth at midpoint |
| Skyrizi | Published consensus $5.49B | About 24% growth |
| Rinvoq | Published consensus $2.47B | About 22% growth |
| Humira | Published consensus $744M | About 37% decline |
Product estimates come from a published Zacks consensus snapshot, while the EPS consensus is corroborated by TipRanks. (zacks.com)
AbbVie originally guided Q2 adjusted EPS to $3.74–$3.78. On July 6, it disclosed $291 million of acquired IPR&D and milestone expense, reducing Q2 guidance by $0.17 per share to $3.57–$3.61. Full-year adjusted EPS guidance was correspondingly reduced from $14.08–$14.28 to $13.91–$14.11. (sec.gov)
That creates two relevant tests:
The second is more informative. A headline EPS result near $3.60 can still represent a strong quarter if product sales and underlying margins outperform.
Q1 immunology revenue increased 14.3% operationally. Skyrizi generated $4.483 billion, up 29.2% operationally, while Rinvoq produced $2.119 billion, up 20.2%. Humira declined to $688 million as biosimilar erosion continued. AbbVie raised its full-year forecasts to approximately $21.6 billion for Skyrizi and $10.2 billion for Rinvoq. (news.abbvie.com)
Together, current consensus estimates for Skyrizi and Rinvoq represent almost 48% of expected Q2 revenue. Small percentage deviations in these products therefore matter more than beats or misses across most of the remaining portfolio.
On July 29, the European Commission approved Rinvoq for severe alopecia areata and non-segmental vitiligo. Rinvoq is the first systemic medication approved in the EU for non-segmental vitiligo, while both indications remain under FDA review in the United States. (news.abbvie.com)
These approvals will not materially affect Q2 revenue, but management’s launch expectations can influence longer-term estimates. Investors should listen for:
Q1 neuroscience revenue was $2.875 billion, up 24.3% operationally. The principal contributors included:
AbbVie’s investment case is becoming less dependent on immunology because migraine, psychiatry and Parkinson’s disease are all scaling simultaneously. A good Q2 would show:
AbbVie previously said it expected a U.S. regulatory decision for tavapadon in the third quarter. If approved, the once-daily oral Parkinson’s therapy would complement Vyalev and give AbbVie exposure to patients earlier in the treatment pathway. The filing was supported by three positive Phase 3 studies. (news.abbvie.com)
Investors should look for a more precise regulatory and launch timeline, commercial staffing updates and any change to AbbVie’s expectation that its Parkinson’s franchise can eventually exceed $5 billion.
Q1 aesthetics revenue increased 5.1% operationally, but the components diverged:
The Q2 questions are straightforward:
The short-duration neurotoxin Boey received approval in Canada in June and Europe in July. Its effect can begin within hours and typically lasts two to three weeks, potentially expanding the toxin category among consumers hesitant to commit to longer-lasting treatment. (news.abbvie.com)
The near-term financial impact will be limited, but investors should watch European launch timing and management’s approach to resolving the U.S. manufacturing-related complete response letter.
Oncology was AbbVie’s weakest major segment in Q1, declining 3% operationally. Venclexta continued growing, but Imbruvica fell approximately 25% because of competition and Medicare drug-pricing effects. (news.abbvie.com)
Investors should expect continued Imbruvica pressure. The more important issue is whether Venclexta, Elahere, Epkinly and the development pipeline can return the franchise to sustainable growth.
The positive development was EPCORE DLBCL-4: epcoritamab plus lenalidomide reduced the risk of progression or death by approximately 60% under one of the study’s censoring approaches versus R-GemOx. AbbVie and Genmab plan discussions with regulators. (news.abbvie.com)
The negative development was clarification that the separate EPCORE DLBCL-1 study did not meet its sole U.S. primary endpoint of overall survival. (news.abbvie.com)
Management will likely face questions about:
A clear regulatory explanation matters more to the stock than a small Q2 oncology sales variance.
AbbVie already raised its outlook after Q1, forecasting approximately $67.3 billion of 2026 revenue and raising several product assumptions. The company then mechanically reduced EPS guidance for the newly disclosed Q2 IPR&D expense.
The cleanest bullish signal would be an operational guidance increase that more than offsets accounting noise. Investors should examine:
If AbbVie merely reiterates the reduced $13.91–$14.11 EPS range without explaining underlying operating upside, the market may interpret that as conservative—or as evidence that estimates have caught up with business momentum.
In June, AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion, funded with debt. Apogee’s lead asset, zumilokibart, is a long-acting IL-13 antibody entering Phase 3 development in atopic dermatitis, with additional respiratory opportunities. AbbVie expects the transaction to close in Q3. (investors.abbvie.com)
The deal is expected to reduce adjusted EPS by approximately:
AbbVie expects accretion beginning in 2032 and is targeting a return to approximately 2x net leverage within two to three years of closing. (investors.abbvie.com)
That dilution is separate from current reported guidance while the transaction remains pending. Management should ideally reconcile:
The strategic rationale is credible—AbbVie is buying a late-stage immunology platform in large, underpenetrated markets—but the valuation places considerable weight on successful Phase 3 development and eventual commercial execution.
ABBV closed July 30 at approximately $257.41. At that price, the shares trade at roughly:
The first multiple is based on the $13.91–$14.11 reported adjusted range; the second is intended only to illustrate underlying earnings power rather than provide a directly comparable company metric. (abbvie.gcs-web.com)
That is not an extreme valuation for AbbVie’s current growth, but it leaves less room for an ordinary “meet and maintain” quarter. With Skyrizi, Rinvoq and neuroscience already expected to perform strongly, the stock probably needs either a meaningful commercial beat or a guidance increase to generate substantial additional upside.
The report is primarily a test of whether Skyrizi and Rinvoq can remain ahead of a rapidly rising bar. If they do—and neuroscience continues to compound at a high rate—AbbVie can sustain one of the stronger large-cap pharma growth profiles despite Humira and Imbruvica erosion.
The secondary question is whether management can preserve that operating strength while funding an aggressive pipeline strategy. A strong quarter should therefore include not only good product numbers, but also a clean guidance bridge, disciplined Apogee financing commentary and credible answers on oncology replacement assets.